oral reversible ERK1/2 kinase inhibitor

combo eff. w/ MEKi in mKRAS model; in Ph. I

from historical kinase sel. data, SBDD + opt.

Mol. Cancer Ther. Dec. 3, 2020

AstraZeneca, Cambridge, UK

Structure of oral reversible ERK1/2 kinase inhibitor AZD0364

AstraZeneca oral reversible ERK1/2 kinase inhibitor


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: